Survey of treatment recommendations for anaplastic oligodendroglioma Journal Article

   


Authors: Abrey, L. E.; Louis, D. N.; Paleologos, N.; Lassman, A. B.; Raizer, J. J.; Mason, W.; Finlay, J.; Macdonald, D. R.; Deangelis, L. M.; Cairncross, J. G.
Article Title: Survey of treatment recommendations for anaplastic oligodendroglioma
Abstract: Anaplastic oligodendroglioma is a malignant brain tumor uniquely sensitive to treatment with both chemotherapy and radiotherapy. There are few prospective clinical trials for newly diagnosed patients and multiple approaches to the treatment of these patients. This study explored the recommended treatment offered by experts in neuro-oncology. A Web-based survey was developed and distributed to 800 members of the Society of Neuro-Oncology (SNO) who had an e-mail address listed with SNO. Questions addressed use of molecular genetic information and treatment recommendations. A total of 99 clinical SNO members (20%) responded. The majority reported practicing at an academic center in the United States. Two-thirds of respondents see more than five patients with newly diagnosed anaplastic oligodendroglioma annually. Molecular genetic testing was requested for more than 75% of patients, and the results significantly influenced treatment recommendations (p = 0.000003). Regardless of molecular genetic status, the most commonly recommended treatment was the use of concurrent temozolomide and radiotherapy followed by adjuvant temozolomide (18%-34%). The current survey demonstrates that although neuro-oncologists have embraced the use of molecular genetic studies in newly diagnosed anaplastic oligodendroglioma, treatment recommendations vary widely and are often independent of the molecular data. Copyright 2007 by the Society for Neuro-Oncology.
Keywords: treatment outcome; antineoplastic agents; united states; cancer patient; combined modality therapy; temozolomide; molecular genetics; brain neoplasms; physician's practice patterns; treatment indication; radiotherapy; vincristine; lomustine; procarbazine; fluorescence in situ hybridization; data collection; malignant neoplastic disease; oligodendroglioma; heterozygosity loss; molecular biology; genetic polymorphism; anaplastic oligodendroglioma; survey; 1p; 19q; molecular genetic studies; treatment recommendations
Journal Title: Neuro-Oncology
Volume: 9
Issue: 3
ISSN: 1522-8517
Publisher: Oxford University Press  
Date Published: 2007-07-01
Start Page: 314
End Page: 318
Language: English
DOI: 10.1215/15228517-2007-002
PUBMED: 17435180
PROVIDER: scopus
PMCID: PMC1907408
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-34547476243&partnerID=40&md5=7b507bf7f08d1d475b99c8aba0aa6bf1
Notes: --- - "Cited By (since 1996): 32" - "Export Date: 17 November 2011" - "CODEN: NEURJ" - "Source: Scopus"
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Lisa De Angelis
    576 De Angelis
  2. Andrew Lassman
    111 Lassman
  3. Lauren E Abrey
    278 Abrey
Related MSK Work